ORIGINAL ARTICLE: PDF OnlyZerbe Melissa B. R.N. D.N.Sc.; Parkerson, Sara G. R.N., M.S.N., O.C.N.; Ortlieb, Maureen Lynch R.N., M.S.N.; Spitzer, Thomas M.D.Cancer Nursing: June 1992 - p 196-205 Buy Abstract The pattern of oral mucositis and related treatment variables was studied in 20 bone marrow transplant patients. Patients received either total body irradiation (TB1) or busulfan in combination with cyclophosphamide and etoposide as pretransplant conditioning. Daily oral assessment scores were analyzed. Mucosl changes began 2 days before transplant and peaked 8 days after transplant. There was a trend far patients receiving TB1 to have slightly higher oral scores during the first week posttransplant than patients receiving busulfan. The TB1 patients averaged almost twice the number of days of continuous intravenous morphine infusion for oral pain and 6 additional days of total parenteral nutrition when compared with patients receiving busulfan. Subjects who died during aplasia manifested mucositis that gradually worsened and did not return to baseline. Differences in oral status based on type of transplant, either autologous or allogeneic, were not shown in this study. © Lippincott-Raven Publishers.